expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026 Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other ...
Cellebrite is indebted to Yossi Carmil. He is a rare CEO – one who has led the Company from its days as a small entrepreneurial start up through a successful market focus shift, major product and ...